iTeos Therapeutics Inc. (ITOS) Social Stream
iTeos Therapeutics Inc (ITOS) Price Targets From Analysts
Use the tables below to see what analysts covering iTeos Therapeutics Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 28 weeks, ITOS's average price target has gone up $1.
Over the past 51 weeks, ITOS's average upside potential has been 78.17%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
ITOS Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 30 weeks, ITOS's average broker recommendation rating improved by 0.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- iTeos Therapeutics Inc's number of analysts covering the stock is greater than 167.94% of all US stocks.
- In terms of how iTeos Therapeutics Inc fares relative to stocks in the small market cap category, note that its average analyst price target is higher than 523.9% of that group.
- In the context of Pharmaceutical Products stocks, iTeos Therapeutics Inc's upside potential (average analyst target price relative to current price) is greater than 124.6% of them.
- iTeos Therapeutics Inc's variance in analysts' estimates is lower than -46.92% of Pharmaceutical Products stocks.
In the Pharmaceutical Products industry, IPSC, IPHA, and INMB are the three stocks most similar to iTeos Therapeutics Inc regarding the price target and analyst recommendation information presented here.
What is the outlook for ITOS? Use POWR Ratings for clearer insight into price direction.